Verisante Technology this week announced several milestones in the development of its Raman spectroscopy-based cancer detection technology.
The company said that it has completed a clinical trial investigating the use of its Verisante Core device for the detection of lung cancer; launched a clinical study on use the Core for the detection of colon cancer; and entered a collaboration with the British Columbia Cancer Agency and China's Fujian Normal University to develop the Core device for detection of nasopharyngeal cancer.
Led by University of British Columbia researcher Stephen Lam, the Core lung cancer trial has collected data on more than 300 lung cancer patients and statistical analysis is now underway. That study builds upon a pilot study investigating use of the Core in lung cancer diagnoses, in which it was able to detect pre-neoplastic lesions with a sensitivity of 96 percent and a specificity of 91 percent.
The colonoscopy study, meanwhile, is being led by Vancouver General Hospital researcher Isabella Tai. Thus far, measurements on two patients using the Core device have confirmed its functionality in this setting, the company said.
The company also continues to market its Raman-based Aura skin cancer detection device, which it launched at the beginning of the year (PM 2/1/2013). It currently has distribution of the device in Canada, Germany, Austria, Liechtenstein, Switzerland, the UK, and Ireland.